BC
TTNP

Broadfin Capital’s Titan Pharmaceuticals TTNP Stock Holding History

Broadfin Capital’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-211
Closed -$3.38M – 85
2015
Q4 		$3.38M Buy
+211
New +$3.44M 0.21% 76

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $150M AUM 32.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital's TTNP Position: Q1 2016 in Review

Broadfin Capital sold out of Titan Pharmaceuticals (TTNP) in Q1 2016, closing a stake of 211 shares — an estimated $3.38M sold.

Broadfin Capital first reported a position in TTNP in Q4 2015 and held it in 1 quarter. The position peaked at $3.38M in Q4 2015. 15 funds tracked by Wall St. Rank hold TTNP as of Q1 2016.

  • Broadfin Capital reported no remaining Titan Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Broadfin Capital sold 211 Titan Pharmaceuticals shares in Q1 2016, an estimated $3.38M.
  • Broadfin Capital first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Broadfin Capital's Titan Pharmaceuticals position peaked at $3.38M in Q4 2015.
  • 15 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.